Article
Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
Clinical lung cancer - 1 Jan 2015
Kuiper Justine L, Heideman Danielle A M, Würdinger Tom, Grünberg Katrien, Groen Harry J M, Smit Egbert F
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown improved progression-free survival (PFS) and overall survival (OS) over chemotherapy in a molecularly defined subgroup of advanced non-small-cell lung cancer (NSCLC) patients (ie, patients with an activating mutation in the EGFR gene). Nevertheless, all EGFR-mutated NSCLC patients develop TKI resistance eventually and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.